VCP
IBB icon

Verus Capital Partners’s iShares Biotechnology ETF IBB Stock Holding History

Verus Capital Partners’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$121K Hold
1,125
– – 0.04% 270
2019
Q4 		$136K Buy
+1,125
New +$126K 0.04% 296

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Verus Capital Partners's IBB Position: Q1 2020 in Review

Verus Capital Partners held its iShares Biotechnology ETF (IBB) position steady in Q1 2020 at 1,125 shares worth $121K. The position accounts for 0.04% of the portfolio, ranked #270.

Verus Capital Partners first reported a position in IBB in Q4 2019 and has held it in 2 quarters since. The position peaked at $136K in Q4 2019. 668 funds tracked by Wall St. Rank hold IBB as of Q1 2020.

  • Verus Capital Partners held 1,125 shares of iShares Biotechnology ETF worth $121K as of Q1 2020.
  • Verus Capital Partners left its iShares Biotechnology ETF share count unchanged in Q1 2020.
  • iShares Biotechnology ETF made up 0.04% of Verus Capital Partners's portfolio in Q1 2020, its #270 holding.
  • Verus Capital Partners first reported a position in iShares Biotechnology ETF in Q4 2019 and has held it in 2 quarters since.
  • Verus Capital Partners's iShares Biotechnology ETF position peaked at $136K in Q4 2019.
  • 668 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.